Abstract:Fetal growth restriction (FGR) affects between 5-10% of all live births. Placental insufficiency is a leading cause of FGR, resulting in reduced nutrient and oxygen delivery to the fetus. Currently, there are no effective in utero treatment options for FGR, or placental insufficiency. We have developed a gene therapy to deliver, via a non-viral nanoparticle, human insulin-like 1 growth factor (hIGF1) to the placenta as potential treatment of placenta insufficiency and FGR. Using a guinea pig maternal nutrient restriction (MNR) model of FGR, we aimed to understand the transcriptional changes within the placenta associated with placental insufficiency that occur prior to/at initiation of FGR, and the impact of short-term hIGF1 nanoparticle treatment. Using RNAsequencing, we analyzed protein coding genes of three experimental groups: Control and MNR dams receiving a sham treatment, and MNR dams receiving hIGF1 nanoparticle treatment. Pathway enrichment analysis comparing differentially expressed genelists in sham-treated MNR placentas to Control revealed upregulation of pathways associated with degradation and repair of genetic information and downregulation of pathways associated with transmembrane transport. When compared to sham-treated MNR placentas, MNR + hIGF1 placentas demonstrated changes to genelists associated with transmembrane transporter activity including ion, vitamin and solute carrier transport. Overall, this study identifies the key signaling and metabolic changes occurring in the placenta contributing to placental insufficiency prior to/at initiation of FGR, and increases our understanding of the pathways that our nanoparticle-mediated gene therapy intervention regulates.

What problem does this paper attempt to address?

The main problems that this paper attempts to solve are fetal growth restriction (FGR) and its main cause - placental insufficiency. Specifically, the research aims to: 1. **Understand the transcriptomic changes in placental insufficiency**: By using a guinea pig maternal nutritional restriction (MNR) model, study the transcriptomic changes before or during placental insufficiency - induced FGR in the second trimester. These changes help to reveal the early mechanisms of placental insufficiency. 2. **Evaluate the effect of a novel gene therapy**: Developed a non - viral nanoparticle delivery system for delivering human insulin - like growth factor 1 (hIGF1) to the placenta, with the hope of improving placental insufficiency and FGR. The research evaluated the impact of this short - term hIGF1 nanoparticle treatment on the placental transcriptome. ### Main research content - **Experimental design**: - **Control group**: Normally - fed guinea pigs. - **MNR group**: Guinea pigs with maternal nutritional restriction, receiving placebo treatment. - **MNR + hIGF1 group**: Guinea pigs with maternal nutritional restriction, receiving hIGF1 nanoparticle treatment. - **Methods**: - Use RNA sequencing (RNA - seq) to analyze the placental protein - coding genes in the three experimental groups. - Conduct differential expression gene analysis and pathway enrichment analysis to compare gene expression changes between different groups. ### Key findings - **Comparison between MNR group and control group**: - In the placentas of the MNR group, pathways related to DNA degradation and repair were up - regulated, while pathways related to transmembrane transport were down - regulated. - The most significantly up - regulated genes included Col16A1 and Cyp17A1, and the most significantly down - regulated genes included Mep1B, Cpvl, Guca2B and Cst6. - **Comparison between MNR + hIGF1 group and MNR group**: - After hIGF1 nanoparticle treatment, pathways related to transmembrane transport activities (such as ion, vitamin and solute carrier transport) changed. - In the treatment group, pathways related to metabolic processes decreased, indicating that hIGF1 nanoparticles may support fetal growth by adjusting placental function. ### Conclusions - **Early mechanisms of placental insufficiency**: The research revealed the early transcriptomic changes in placental insufficiency, which may lead to the occurrence of FGR. - **Potential of hIGF1 nanoparticle treatment**: Short - term hIGF1 nanoparticle treatment can change gene expressions related to transmembrane transport and metabolic processes, indicating that this treatment method has potential value in improving placental function and preventing FGR. Through these studies, the authors hope to provide a scientific basis for the future development of more effective intrauterine treatment methods for FGR.

Mid-pregnancy placental transcriptome in a model of placental insufficiency with and without novel intervention

Maternal-fetal interfaces transcriptome changes associated with placental insufficiency and a novel gene therapy intervention

Placental treatment with insulin-like growth factor 1 via nanoparticle differentially impacts vascular remodeling factors in guinea pig sub-placenta/decidua

Placental hIGF1 nanoparticle gene therapy in guinea pigs ameliorates fetal growth restriction-associated changes in hepatic lipid and glucose metabolism-related signaling pathways in a fetal sex-specific manner

Placental Nanoparticle-mediated IGF1 Gene Therapy Corrects Fetal Growth Restriction in a Guinea Pig Model

Anti-placental Growth Factor Antibody Ameliorates Hyperoxia-Mediated Impairment of Lung Development in Neonatal Rats

Differential microRNA expression in human placentas of term intra-uterine growth restriction that regulates target genes mediating angiogenesis and amino acid transport

Insulin-like growth factor 1 signaling in the placenta requires endothelial nitric oxide synthase to support trophoblast function and normal fetal growth

Transplacental Nutrient Transport Mechanisms of Intrauterine Growth Restriction in Rodent Models and Humans

Integrated Placental Modelling of Histology with Gene Expression to Identify Functional Impact on Fetal Growth

Liposome-Encapsulated Anti-inflammatory Proteins for Targeted Delivery to the Placenta to Treat Fetal Growth Restriction

MicroRNA Expression Profiles and Networks in Placentas Complicated with Selective Intrauterine Growth Restriction.

PSII-34 Placental GLUT3 (SLC2A3) RNA interference: Impact on fetal growth at mid-gestation

The placental blood perfusion and LINC00473-mediated promotion of trophoblast apoptosis in fetal growth restriction

A genetically small fetus impairs placental adaptations near term

Sirtuin 1 is a potential therapeutic candidate gene for fetal growth restriction via insulin-like 4

Nanoparticle-mediated delivery of placental gene therapy via uterine artery catheterization in a pregnant rhesus macaque

Fetal growth restriction exhibits various mTOR signaling in different regions of mouse placentas with altered lipid metabolism

Down-regulation of placental folate transporters in intrauterine growth restriction

Maternal Curcumin Supplementation Ameliorates Placental Function and Fetal Growth in Mice with Intrauterine Growth Retardation†